A Panobinostat Presurgery

Summary

In the current study, the investigators will evaluate intratumoral pharmacodynamic and pharmacokinetic data associated with the administration of the HDACI, Panobinostat, among recurrent GBM patients. In addition, this study will evaluate the safety and tolerability of this agent, as well as evidence of anti-tumor activity in the patient population.

Timeline

Start

2010-04

Primary completion

2011-04

Completion

2012-04

Outcome

Outcome not reported

Stopped (Enrollment): “No subjects were enrolled on this study, so study was closed and IND withdrawn.”

Drugs

Indications